A Phase 2, Open-label Study of the Safety, Tolerability and Immunogenicity of a Meningococcal B Vaccine When Administered at a 0, 2, 6 Months and of a Single Dose of Meningococcal ACWY Conjugate Vaccine in Healthy Adults Aged 18-65 Years.

Trial Profile

A Phase 2, Open-label Study of the Safety, Tolerability and Immunogenicity of a Meningococcal B Vaccine When Administered at a 0, 2, 6 Months and of a Single Dose of Meningococcal ACWY Conjugate Vaccine in Healthy Adults Aged 18-65 Years.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Jul 2015

At a glance

  • Drugs Meningococcal vaccine group B; Meningococcal vaccine groups A C Y W-135 conjugate
  • Indications Meningococcal group A infections; Meningococcal group B infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections; Meningococcal infections
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms MenOccy
  • Most Recent Events

    • 07 Apr 2012 Actual initiation date changed from Dec 2009 to Jul 2010 as reported by ClinicalTrials.gov.
    • 27 Mar 2012 Actual patient number 38 added as reported by ClinicalTrials.gov.
    • 27 Mar 2012 Actual initiation date Mar 2012 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top